Pub. Date : 2020 Oct-Dec
PMID : 33154302
4 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Impact of ERCC1 gene polymorphisms on response to cisplatin based therapy in oral squamous cell carcinoma (OSCC) patients. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 2 | Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 3 | Background and Objectives: Cisplatin is one of the major drugs that used in the treatment of oral cancer.Excision repair cross-complementation group 1 (ERCC1) is a key DNA repair gene in the nucleotide excision repair pathway which is activated in the repair of intra- and interstrand DNA crosslink caused by platinum-based treatment. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |
| 4 | The aim of this study was to investigate the association between polymorphisms in ERCC1 (C118T & C8092A) genes and the response to cisplatin-based chemotherapy. | Cisplatin | ERCC excision repair 1, endonuclease non-catalytic subunit | Homo sapiens |